IP Library Patent Application 15118124
Patent Application
App. No. 15/118,124

COMPOSITIONS AND METHODS FOR TREATING DIABETES AND LIVER DISEASES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/118,124
Abstract

Compounds, compositions, and methods are described herein for treating diabetes, fatty liver diseases, fibrotic diseases, such as liver and pulmonary fibrosis, and hepatocellular carcinoma.

Claims (49)

1 . A method for treating diabetes in a host animal, the method comprising the step of administering to the host animal an effective amount of a composition comprising one or more compounds of the formula

or a pharmaceutically acceptable salt thereof, or a hydroxyl or amino prodrug thereof; wherein:

X is a divalent radical selected from the group consisting of

where X is connected at each (*) atom;

W 11 is hydroxy or a derivative thereof; W 12 is H, or hydroxy or a derivative thereof; or W 11 and W 12 are taken together with the attached carbon atoms to form an optionally substituted heterocycle containing oxygen or nitrogen or both oxygen and nitrogen;

Q is O or (NR, H); where R is hydrogen or optionally substituted alkyl; or R and W11 are taken together to form an aminal ether; and Q 1 is hydroxy or a derivative thereof or amino or a derivative thereof;

R A is hydroxy or a hydroxy derivative, or a saccharide attached at oxygen; and Z is hydrogen; or R A and Z are taken together with the attached carbon to form a C═O group;

R B is an amino containing saccharide;

R C is hydroxy or a derivative thereof; or

R C and Q are taken together to form an enol ether; or

R C and W 12 and Q are taken together to form a ketal; and

R F is H or F.

2 . A method for treating a FLD in a host animal, the method comprising the step of administering to the host animal an effective amount of a composition comprising one or more compounds of the formula

or a pharmaceutically acceptable salt thereof, or a hydroxyl or amino prodrug thereof; wherein:

X is a divalent radical selected from the group consisting of

where X is connected at each (*) atom;

W 11 is hydroxy or a derivative thereof; W 12 is H, or hydroxy or a derivative thereof; or W 11 and W 12 are taken together with the attached carbon atoms to form an optionally substituted heterocycle containing oxygen or nitrogen or both oxygen and nitrogen;

Q is O or (NR, H); where R is hydrogen or optionally substituted alkyl; or R and W11 are taken together to form an aminal ether; and Q 1 is hydroxy or a derivative thereof or amino or a derivative thereof;

R A is hydroxy or a hydroxy derivative, or a saccharide attached at oxygen; and Z is hydrogen; or R A and Z are taken together with the attached carbon to form a C═O group;

R B is an amino containing saccharide;

R C is hydroxy or a derivative thereof; or

R C and Q are taken together to form an enol ether; or

R C and W 12 and Q are taken together to form a ketal; and

R F is H or F.

3 . The method of claim 2 wherein the FLD is NASH.

4 . The method of claim 1 wherein at least one compound is of the formula

or a pharmaceutically acceptable salt thereof.

5 . The method of claim 1 wherein at least one compound is of the formula

or a pharmaceutically acceptable salt thereof; where

C is H or alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, each of which is optionally substituted;

B is a bond, or B is an optionally substituted heteroaryl; and

A is a bond, or A is an optional linker formed from one or more fragments selected from the group consisting of O, C(O), C, CR, CR 2 , N, and NR, and combinations thereof, where each R is independently selected in each instance from the group consisting of hydrogen and optionally substituted alkyl.

6 . The method of claim 1 wherein at least one compound is of the formula

or a pharmaceutically acceptable salt thereof.

7 . The method of claim 1 wherein Z is H and R A is hydroxy or a derivative thereof.

8 . The method of claim 1 wherein Z is H and R A is cladinosyl.

9 . The method of claim 1 wherein Z and R A are taken together with the attached carbon to form C═O.

10 . The method of claim 1 wherein R B is desosaminyl.

11 . The method of claim 1 wherein R B is desmethyl desosaminyl, O-acyl desosaminyl, or O-alkyl desosaminyl.

12 . The method of claim 1 wherein R B is a radical of the formula

where each R N1 is independently selected in each instance from the group consisting of H and acyl, and alkyl, cycloalkyl, arylalkyl, and heteroarylalkyl, each of which is optionally substituted, providing that at least one R N1 is not methyl; or both R N1 are taken together with the attached nitrogen to form a nitrogen containing heterocycle; and R O is H or acyl, or alkyl, cycloalkyl, arylalkyl, and heteroarylalkyl, each of which is optionally substituted; or R O and one R N1 are taken together with the attached atoms to form an oxygen and nitrogen containing heterocycle.

13 . The method of claim 1 wherein R B is a radical of the formula

14 . The method of claim 1 wherein R C is hydroxy or alkoxy.

15 . The method of claim 1 wherein R F is F.

16 . The method of claim 5 wherein A is alkylene.

17 . The method of claim 5 wherein B is an imidazole radical or a 1,2,3-triazole radical.

18 . The method of claim 5 wherein C is an optionally substituted heteroaryl or optionally substituted heteroarylalkyl radical.

19 . The method of claim 1 wherein the compound is selected from the group consisting of solithromycin, roxithromycin, azithromycin, flurithromycin, and dirithromycin, and pharmaceutically acceptable salts thereof, and combinations thereof.

20 . The method of claim 5 wherein C is optionally substituted aryl or optionally substituted arylalkyl.

Assignments (1)
SECURITY INTEREST Recorded Jan 8, 2018
From: MELINTA THERAPEUTICS, INC.; REMPEX PHARMACEUTICALS, INC.; CEMPRA PHARMACEUTICALS, INC.; CEM-102 PHARMACEUTICALS, INC.
To: CORTLAND CAPITAL MARKET SERVICES LLC, AS AGENT
Reel/Frame 045019/0552 →